×
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
S&P 500   3,911.74 (+3.06%)
DOW   31,500.68 (+2.68%)
QQQ   294.61 (+3.43%)
AAPL   141.66 (+2.45%)
MSFT   267.70 (+3.41%)
META   170.16 (+7.19%)
GOOGL   2,359.50 (+5.11%)
AMZN   116.46 (+3.58%)
TSLA   737.12 (+4.52%)
NVDA   171.26 (+5.55%)
NIO   24.08 (+4.47%)
BABA   117.62 (+4.91%)
AMD   87.08 (+5.64%)
MU   58.44 (+3.95%)
CGC   3.77 (+4.72%)
T   20.99 (+1.84%)
GE   67.08 (+4.70%)
F   12.01 (+3.89%)
DIS   97.78 (+3.69%)
AMC   12.47 (+3.49%)
PFE   51.59 (+2.99%)
PYPL   77.68 (+5.24%)
NFLX   190.85 (+5.03%)
NASDAQ:MRUS

Merus Stock Forecast, Price & News

$22.08
+0.74 (+3.47%)
(As of 06/24/2022 12:00 AM ET)
Add
Compare
Today's Range
$21.00
$22.50
50-Day Range
$13.98
$24.28
52-Week Range
$13.47
$33.09
Volume
2.05 million shs
Average Volume
251,127 shs
Market Capitalization
$961.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$41.43
30 days | 90 days | 365 days | Advanced Chart

Receive MRUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merus and its competitors with MarketBeat's FREE daily newsletter.

MRUS Stock Forecast (MarketRank)

Overall MarketRank

1.90 out of 5 stars

Medical Sector

689th out of 1,418 stocks

Pharmaceutical Preparations Industry

333rd out of 679 stocks

Analyst Opinion: 3.4Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
Merus logo

About Merus (NASDAQ:MRUS)

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

MRUS Stock News Headlines

Analysts Set Merus (NASDAQ:MRUS) Price Target at $40.83
Merus (NASDAQ:MRUS) Shares Gap Up to $18.98
Merus (NASDAQ:MRUS) Shares Up 8.9%
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRUS
Fax
N/A
Employees
117
Year Founded
N/A

Company Calendar

Last Earnings
5/09/2022
Today
6/24/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$41.43
High Stock Price Forecast
$45.00
Low Stock Price Forecast
$33.00
Forecasted Upside/Downside
+87.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85714285714286
Research Coverage
7 Analysts

Profitability

Net Income
$-66.82 million
Net Margins
-143.77%
Pretax Margin
-143.58%

Debt

Sales & Book Value

Annual Sales
$49.11 million
Book Value
$8.15 per share

Miscellaneous

Free Float
42,287,000
Market Cap
$961.58 million
Optionable
Not Optionable
Beta
1.12














Merus Frequently Asked Questions

Should I buy or sell Merus stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Merus in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Merus stock.
View analyst ratings for Merus
or view top-rated stocks.

What is Merus' stock price forecast for 2022?

7 analysts have issued 1 year target prices for Merus' shares. Their MRUS stock forecasts range from $33.00 to $45.00. On average, they predict Merus' stock price to reach $41.43 in the next twelve months. This suggests a possible upside of 87.6% from the stock's current price.
View analysts' price targets for Merus
or view top-rated stocks among Wall Street analysts.

How has Merus' stock price performed in 2022?

Merus' stock was trading at $31.80 at the beginning of 2022. Since then, MRUS shares have decreased by 30.6% and is now trading at $22.08.
View the best growth stocks for 2022 here
.

When is Merus' next earnings date?

Merus is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Merus
.

How were Merus' earnings last quarter?

Merus (NASDAQ:MRUS) announced its quarterly earnings results on Monday, May, 9th. The biotechnology company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.23. The biotechnology company had revenue of $11.66 million for the quarter, compared to analyst estimates of $8.55 million. Merus had a negative trailing twelve-month return on equity of 29.02% and a negative net margin of 143.77%.
View Merus' earnings history
.

Who are Merus' key executives?

Merus' management team includes the following people:
  • Dr. Sven Ante Lundberg M.D., CEO, Pres, Principal Financial Officer & Exec. Director (Age 59, Pay $990.53k)
  • Mr. Peter B. Silverman J.D., Exec. VP, Gen. Counsel, Chief Intellectual Property Officer and Head of Utrecht & US Legal (Age 44, Pay $677.96k)
  • Mr. Hui Liu Ph.D., Chief Bus. Officer, Exec. VP & Head of Merus U.S. (Age 55, Pay $605.93k)
  • Dr. Hennie Hoogenboom, Co-Founder and Scientific Advisor
  • Harry Shuman, Chief Accounting Officer
  • Mr. Cornelis Adriaan de Kruif Ph.D., CTO & Exec. VP (Age 57)
  • Dr. Cecilia Anna Wilhelmina Geuijen Ph.D., Chief Scientific Officer & Sr. VP
  • Ms. Jillian Connell, VP of Investor Relations & Corp. Communications
  • Mr. Alexander Berthold Hendrik Bakker Ph.D., Chief Devel. Officer & Exec. VP (Age 55)
  • Dr. Andrew Joe M.D., Chief Medical Officer & Sr. VP (Age 55)

What other stocks do shareholders of Merus own?

When did Merus IPO?

(MRUS) raised $64 million in an IPO on Thursday, May 19th 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. Citigroup and Jefferies served as the underwriters for the IPO and Guggenheim Securities and Wedbush PacGrow were co-managers.

What is Merus' stock symbol?

Merus trades on the NASDAQ under the ticker symbol "MRUS."

Who are Merus' major shareholders?

Merus' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (6.79%), Frazier Life Sciences Management L.P. (1.44%), BlackRock Inc. (1.23%), Ghost Tree Capital LLC (0.92%), Lord Abbett & CO. LLC (0.91%) and Silverarc Capital Management LLC (0.75%). Company insiders that own Merus stock include Bvf Partners L P/Il, Kruif John De, Lex Bakker, Mark Throsby, Peter B Silverman and Value Fund L P Biotechnology.
View institutional ownership trends for Merus
.

Which major investors are selling Merus stock?

MRUS stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, BlackRock Inc., Platinum Investment Management Ltd., Acadian Asset Management LLC, Kynam Capital Management LP, and Northern Trust Corp. Company insiders that have sold Merus company stock in the last two years include Bvf Partners L P/Il, Kruif John De, Lex Bakker, Mark Throsby, and Peter B Silverman.
View insider buying and selling activity for Merus
or view top insider-selling stocks.

Which major investors are buying Merus stock?

MRUS stock was purchased by a variety of institutional investors in the last quarter, including Frazier Life Sciences Management L.P., Paradigm Biocapital Advisors LP, Lord Abbett & CO. LLC, Eversept Partners LP, Tekla Capital Management LLC, Goldman Sachs Group Inc., Ghost Tree Capital LLC, and Woodline Partners LP.
View insider buying and selling activity for Merus
or or view top insider-buying stocks.

How do I buy shares of Merus?

Shares of MRUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Merus' stock price today?

One share of MRUS stock can currently be purchased for approximately $22.08.

How much money does Merus make?

Merus (NASDAQ:MRUS) has a market capitalization of $961.58 million and generates $49.11 million in revenue each year. The biotechnology company earns $-66.82 million in net income (profit) each year or ($1.87) on an earnings per share basis.

How many employees does Merus have?

Merus employs 117 workers across the globe.

How can I contact Merus?

Merus' mailing address is YALELAAN 62, UTRECHT P7, 3584 CM. The official website for Merus is www.merus.nl. The biotechnology company can be reached via phone at (130) 253-8800 or via email at [email protected].

This page (NASDAQ:MRUS) was last updated on 6/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.